An open-label, nonrandomized, multi-center, multiple-dose, parallel-group, safety, tolerability, and PK study of Esuberaprost (BPS-314d-MR) in subjects with normal, mild and moderate hepatic impairment.

Trial Profile

An open-label, nonrandomized, multi-center, multiple-dose, parallel-group, safety, tolerability, and PK study of Esuberaprost (BPS-314d-MR) in subjects with normal, mild and moderate hepatic impairment.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Esuberaprost (Primary)
  • Indications Liver disorders; Liver dysfunction
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 07 Jul 2016 New trial record
    • 18 May 2016 Results presented at the 112th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top